| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5fe74855697fef20a2e98a9b005db19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72cfbf45d4a7c9f0b31b0db12db2b979
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f2c548ed7f58bd8412f164b4e0a1dcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bfb02e121b97db80a5c42b4ccfad09c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate |
2000-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66a8f39128a467f8b9843de77cc4ddb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6be2ff92558eebe951c75b5113de105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b735b93dbcfc11a7f9e67dab128358e5 |
| publicationDate |
2001-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0134126-A3 |
| titleOfInvention |
Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) |
| abstract |
The present invention refers to the use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as component for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention. |
| priorityDate |
1999-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |